Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine

Annals of Hematology

Volumn 92, Issue 11, 2013, Pages 1543-1552

  Abáigar, María ^a,b   Ramos, Fernando ^c,d   Benito, Rocío ^a,b   Díez Campelo, María ^b,e   Sánchez Del Real, Javier ^c   Hermosín, Lourdes ^f   Rodríguez, Juan Nicolás ^g   Aguilar, Carlos ^h   Recio, Isabel ⁱ   Alonso, Jose María ^j   De Las Heras, Natalia ^c   Megido, Marta ^k   Fuertes, Marta ^c   Del Cañizo, María Consuelo ^b,e   Hernández Rivas, Jesús María ^a,b,e  

^a Centro de Investigacion del Cancer   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c HOSPITAL DE LEÓN   (Spain)

^d UNIVERSITY OF LEÓN   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f Hospital del SAS   (Spain)

^g HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^h HOSPITAL SANTA BÁRBARA   (Spain)

ⁱ HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^j HOSPITAL RÍO CARRIÓN   (Spain)

^k HOSPITAL EL BIERZO   (Spain)

more..

Author keywords

Acute myeloid leukemia; Azacytidine; Methylation; Myelodysplastic syndromes; Survival

Indexed keywords

APC PROTEIN; ATM PROTEIN; AZACITIDINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; HERMES ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VON HIPPEL LINDAU PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; APC GENE; ARTICLE; ATM GENE; BRCA2 GENE; CANCER PROGNOSIS; CASP8 GENE; CD44 GENE; CDH13 GENE; CDKN1B GENE; CDKN2A GENE; CDKN2B GENE; CHFR GENE; CONTROLLED STUDY; CYTOGENETICS; DAPK1 GENE; DNA METHYLATION; ESR1 GENE; FEMALE; FHIT GENE; GENETIC ASSOCIATION; GSTP1 GENE; HIC1 GENE; HUMAN; HUMAN TISSUE; IGSF4 GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MLH1 GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PTEN GENE; RARB GENE; RASSF1 GENE; TIMP3 GENE; TP73 GENE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VHL GENE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CYTOGENETIC ANALYSIS; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84885571972     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1799-9     Document Type: Article

References (38)

1. Corey SJ, Minden MD, Barber DL et al (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7:118-129
2. Nimer SD (2008) Myelodysplastic syndromes. Blood 111:4841-4851. doi: 10.1182/blood-2007-08-078139
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223-232. doi: 10.1016/S1470-2045(09)70003-8
4. Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29:516-523. doi: 10.1200/JCO.2010.31.0854
5. Kantarjian HM, O'Brien S, Shan J et al (2007) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109:265-273
6. Musolino C, Sant'antonio E, Penna G et al (2010) Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol 84:463-473. doi: 10.1111/j.1600-0609. 2010.01433.x
7. Gotze K, Muller-Thomas C, Peschel C (2009) The role of azacitidine in the management of myelodysplastic syndromes (MDS). Cancer Manag Res 1:119-130
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569. doi: 10.1200/JCO.2009.23.8329
9. Itzykson R, Thepot S, Quesnel B et al (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117:403-411. doi: 10.1182/blood-2010- 06-289280
10. Raj K, John A, Ho A et al (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937-1944
11. Shen L, Kantarjian H, Guo Y et al (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605-613. doi: 10.1200/JCO.2009.23.4781
12. Figueroa ME, Skrabanek L, Li Y et al (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114:3448-3458. doi: 10.1182/blood-2009-01-200519
13. Aggerholm A, Holm MS, Guldberg P et al (2006) Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76:23-32
14. Aoki E, Uchida T, Ohashi H et al (2000) Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 14:586-593
15. Hess CJ, Errami A, Berkhof J et al (2008) Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 49:1132-1141. doi: 10.1080/10428190802035990
16. Lin J, Yao DM, Qian J et al (2008) Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 32:1541-1545. doi: 10.1016/j.leukres. 2008.02.008
17. Valencia A, Cervera J, Such E et al (2011) Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. Leuk Res 35:479-483. doi: 10.1016/j.leukres.2010.08.012
18. Itzykson R, Kosmider O, Cluzeau T et al (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. doi: 10.1038/leu.2011
19. Simo-Riudalbas L, Melo SA, Esteller M (2011) DNMT3B gene amplification predicts resistance to DNA demethylating drugs. Genes Chromosomes Cancer 50:527-534. doi: 10.1002/gcc.20877
20. Metzeler KH, Walker A, Geyer S et al (2012) DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 26:1106-1107. doi: 10.1038/leu.2011.342
21. Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951. doi: 10.1182/blood-2009-03-209262
22. Hernandez JM, Gonzalez MB, Granada I et al (2000) Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo. Haematologica 85:481-485
23. Shaffer LG, Slovak ML, Campbell LJ (2009) An international system for human cytogenetic nomenclature (2009): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S. Karger AG, Basel. ISBN 978-3-8055-8985-7
24. Gonzalez MB, Hernandez JM, Garcia JL et al (2004) The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma. Haematologica 89:1213-1218
25. Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425
26. Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474. doi: 10.1182/blood-2009-07-235358
27. Nygren AO, Ameziane N, Duarte HM et al (2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33:e128
28. Schouten JP, McElgunn CJ, Waaijer R et al (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
29. Byrd JC, Mrozek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336
30. Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5,876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365. doi: 10.1182/blood-2009-11-254441
31. Cordoba I, Gonzalez-Porras JR, Nomdedeu B et al (2011) Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer 118:127-133. doi: 10.1002/cncr.26279
32. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
33. Iwai M, Kiyoi H, Ozeki K et al (2005) Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia 19:1367-1375
34. Jiang Y, Dunbar A, Gondek LP et al (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315-1325. doi: 10.1182/blood-2008-06-163246
35. Berginc G, Bracko M, Glavac D (2010) MS-MLPA reveals progressive age-dependent promoter methylation of tumor suppressor genes and possible role of IGSF4 gene in colorectal carcinogenesis of microsatellite instable tumors. Cancer Invest 28:94-102. doi: 10.3109/07357900902849673
36. Castro M, Grau L, Puerta P et al (2010) Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 8:86. doi: 10.1186/1479-5876-8-86
37. Dikow N, Nygren AO, Schouten JP et al (2007) Quantification of the methylation status of the PWS/AS imprinted region: comparison of two approaches based on bisulfite sequencing and methylation-sensitive MLPA. Mol Cell Probes 21:208-215
38. Marzese DM, Gago FE, Vargas-Roig LM, Roque M (2010) Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 24:271-280. doi: 10.1016/j.mcp.2010.05.002